Comparison of monovision surgery using ICL V4c or femtosecond laser LASIK for myopia correction in the presbyopia age patients

Abstract

To compare the long-term outcomes of monovision surgery using implantable collamer lens (ICL) V4c and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) in myopic patients with early presbyopia. This case series study included 48 eyes of 24 patients (male/female: 10/14, mean age 45.50 ± 3.82 years) and followed-up for 4.5 years (54.00 ± 9.77 months). Patients were examined for spherical equivalent, uncorrected distance visual acuity, corrected distance visual acuity, intraocular pressure, presbyopic add power, visual acuity (VA) (logMAR) of dominant eyes (D-eye), non-dominant eyes (nD-eye), and both eyes (Bi) at 0.4 m, 0.8 m, and 5 m, corneal wavefront aberration, and contrast sensitivity (CS). All surgeries were uneventful. The safety indices of ICL V4c group and FS-LASIK group were 1.17 ± 0.30 and 0.98 ± 0.20 (p < 0.05), and the efficacy indices were 0.79 ± 0.07 and 0.52 ± 0.07 (p < 0.05) respectively. The binocular VA (logMAR) of ICL V4c group and FS-LASIK group at 5.0 m were: 0.02 ± 0.11, 0.18 ± 0.30; 0.8 m: 0.09 ± 0.12, − 0.01 ± 0.11; 0.4 m: − 0.02 ± 0.06, − 0.03 ± 0.08, (p > 0.05 at three distances). Compared with ICL V4c group, lower CS was observed at 1.0 cpd in the FS-LASIK group (1.07 ± 0.31 vs. 0.80 ± 0.51, p = 0.043). Monovision surgery using ICL V4c and FS-LASIK provides good binocular visual acuity at near-to-far distances in myopia patients in the presbyopia age group.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-025-88588-y.

Introduction

In 2015, the global prevalence of presbyopia was estimated at 1.8 billion individuals, which increased to 2.1 billion by 2020^1–3. By the year 2050, it is projected that the population with myopia will reach a staggering number of 4.758 billion people, out of which approximately 938 million are expected to have high myopia⁴. With the aging population, there will be a significant rise in the number of individuals over the age of 40 affected by both myopia and presbyopia. Monovision has emerged as a widely utilized clinical approach for managing myopia in patients with presbyopia^5–7, involving correction of distant vision in the dominant eye (D-eye) and near vision in the non-dominant eye (nD-eye). Various methods can be employed for monovision treatment including frame spectacles, contact lenses, corneal inlays, Implantable Collamer Lens (ICL) implantation, and lens replacement procedures^2,3.

Currently, mainstream refractive surgery like corneal refractive surgery and ICL implantation has great potential for the correction of myopia in the presbyopia age patients^8–10. The safety and efficacy indices were significantly lower in patients > 40 years old 6 months after femtosecond laser small incision lenticule extraction, with astigmatism residue and a tendency of undercorrection⁹. Femtosecond laser fabrication of corneal flaps helps to improve the predictability, accuracy, and stability, and makes laser-assisted in situ keratomileusis (LASIK) surgery safer and more accurate. Femtosecond laser-assisted in situ keratomileusis (FS-LAISK) is potentially used to correct high myopia in the presbyopia age patients^11,12. With the development and clinical application of ICL V4c, the misgivings regarding ICL implantation-related acceleration of cataract formation have been further reduced or even eliminated¹³. A previous study showed that it is safe and effective to correct ametropia in myopic patients aged 40 and above¹⁰.

However, the long-term comparison between ICL V4c and FS-LASIK were frequently neglected in the presbyopia age patients. Therefore, this study aimed to compare the long-term characteristics of visual quality and contrast sensitivity in these patients, thus providing the basis for their clinical application for myopia correction in the presbyopia age patients.

Patients and methods

Subjects

This observational consecutive case series study was conducted at the Eye and Ear, Nose, Throat Hospital of Fudan University, Shanghai, China, between June 2015 and December 2021. 48 eyes of 24 patients with early presbyopia (male/female: 10/14, average age: 45.50 ± 3.82 years, Table 1) were enrolled and recieved binocular FS-LASIK (24 eyes of 12 patients) or ICL V4c implantation (24 eyes of 12 patients) for myopia correction. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University (approval number: 2013015). Written informed consent was obtained from all patients before performing all procedures.

Table 1.

Preoperative patient demographics.

Characteristic	Mean ± SD	Range	ICL V4c Group	FS-LASIK Group	P
Age(years)	45.50 ± 3.82	(40,54)	43.75 ± 2.31	47.25 ± 4.21	0.033
Gender(male/female)	10/14		5/7	5/7	1.000
Axial length(mm)	27.13 ± 2.12	(23.98, 32.11)	28.47 ± 2.10	26.45 ± 1.63	0.001
Refraction sphere(D)	− 9.40 ± 3.90	(− 19.00, − 2.25)	− 11.05 ± 3.42	− 7.74 ± 3.69	0.002
Refraction cylinder (D)	− 1.13 ± 0.93	(− 3.25, 0)	− 1.49 ± 1.07	− 0.77 ± 0.58	0.006
SE (D)	− 9.96 ± 4.00	(− 19.00, − 2.25)	− 11.80 ± 3.36	− 8.13 ± 3.78	0.001
CDVA (LogMAR)	− 0.03 ± 0.07	(− 0.18, 0.22)	0.05 ± 0.08	− 0.01 ± 0.08	0.010
Dominant eye (OD/OS)	14/10	NA	6/6	8/4	NA
ADD (D)	1.02 ± 0.66	(0.50, 2.50)	0.71 ± 0.33	1.33 ± 0.77	0.017
K-flat(D)	43.57 ± 1.37	(40.80, 46.60)	43.34 ± 1.54	43.80 ± 1.15	0.254
K-steep(D)	44.68 ± 1.42	(42.30, 47.20)	44.96 ± 1.64	44.40 ± 1.14	0.174
WTW (mm)	11.86 ± 0.33	(11.00, 12.40)	11.79 ± 0.35	11.94 ± 0.28	0.134

SE, spherical equivalent; CDVA, corrected-distant visual acuity; ADD, presbyopic add power; WTW, white to white.

Values with statistical significance between ICL V4c group and FS-LASIK group are shown in bold.

The inclusion criteria were as follows: (1) participants aged over 40 years with transparent lenses; (2) a myopia progression rate of less than 0.5D per year within a two-year period; (3) no use of soft contact lenses for more than two weeks, or rigid gas permeable contact lenses for more than three months; and (4) presbyopic add power greater than + 0.50 D and corrected visual acuity not lower than 20/20 at intermediate and near distances, respectively. The exclusion criteria were: (1) diagnosis or suspicion of keratoconus; (2) history of active eye disease or systemic diseases; and (3) corneal endothelial cell density (ECD) below 2000 cells/mm² or anterior chamber depth (ACD) below 2.8 mm in the ICL V4c group.

Slit lamp examination and fundus examination were completed after pupillary dilation to check the lens transparency and exclude fundus lesions.

Equipment and measured parameters were: (1) Phoropter (RT-5100, Nidek Technologies, Japan): Spherical equivalent (SE), and corrected-distance VA (CDVA). Card-hole method was used to determine the D-eyes and nD-eyes and Fusion Cross-Cylinder method was used to measure prebyopic add power (ADD) at a 33 cm distance with optimal distance visual acuity correction. (2) Canon Full Auto Tonometer TX-F (Canon, Inc., Tokyo, Japan): Intraocular pressure. (3) Pentacam HR (Oculus Optikgerate Wetzlar, Wetzlar, Germany): Corneal thickness, anterior chamber volume, ACD, anterior chamber angle, and white-to-white. (4) SP-2000P (Topcon Corporation, Kyoto, Japan): ECD. (5) IOL Master 700 (Carl Zeiss AG, Germany): white-to-white. (6) IOL Master 500 (Carl Zeiss AG, Germany): axial length. (7) I.Profiler (Zeiss AG, Germany): corneal aberrations within the 5.00 mm radius of the pupil centre. (8) Adaptive Sensory Technology (AST, American): Area Under Line of Contrast Sensitivity Function (AULCSF), CSF Acuity, and contrast sensitivity (CS) under 1.0, 1.5, 3.0, 6.0, 12.0 and 18.0 cpd. The detailed principle and method have been reported previously.^14,15.

Monovision

The ICL size was determined using the online calculation software provided by STAAR Surgical (http://en.informer.com/icl-power-calculation-software/, Version 3.0). Subsequently, adjustments were made based on the anterior chamber depth (ACD), angle to angle distances, and white-to-white (WTW) measurements obtained from Pentacam and IOL master devices. The targeted spherical equivalent (SE) ranged from − 0.50 to 0.25 D for patients with D-eyes in both the ICL V4c and FS-LASIK groups, while for patients with nD-eyes, it ranged from − 1.75 to − 0.50 D and − 2.25 to − 0.50 D in the two respective groups accordingly. These target values were personally determined according to their preoperative ADD.

We select a presbypic add of 0.50D as a cut off value to test and ask the patient whether to choose the monovision design in the refraction surgery for myopia correction. When the residual myopic diopters on trial was subjectively accepted by patients and it showed superiority in binocular near-to-far distances, the monovision design was selected.Excessive addition for the nD-eyes was not planned in this study because high monovision-induced anisometropia might be correlated with clinical feature like binocular imbalance. ¹⁶.

Surgeries

One experienced surgeon (XZ) performed all surgeries. In FS-LASIK surgery, flap was created in 7.5 mm diameter and 100 µm thickness with standard 90° hinges and 90° side cut angles using a 500 kHz VisuMax femtosecond laser system with a pulse energy of 130 nJ (Carl Zeiss Meditec, Jena, Germany), and stroma was ablated using a MEL 90 excimer laser with a pulse energy of 185 nJ (Carl Zeiss Meditec). The planned optic zone of 6.35 ± 0.25 mm (range 6.10–6.70). After FS-LASIK, a soft contact lens was worn and removed at 1 day postoperatively. The detailed steps are described in a previous study¹⁷. In ICL V4c implantation surgeries, after topical anaesthesia, a viscoelastic agent was injected in the anterior chamber followed with implantation of ICL V4c through the lateral corneal incision. Thereafter, the manipulator was used for ICL adjustment, and a balanced salt solution was used to replace the viscoelastic agent. Postoperatively, antibiotic and steroid eye drops were administered. The detailed steps are described in a previous study¹⁸.

Follow-up

We conducted a 4.5-year follow-up with the period ranging from 45 to 75 months and an average of 54.00 ± 6.77 months. The relevant parameters were assessed at 1 month postoperatively (ECD at 3 months postoperatively) and the final follow-up visit. Subjective satisfaction regarding visual acuity at near and far distances was recorded before surgery, 3-month after surgery, and at the last follow-up visit using a scoring system ranging from 1 to 5: (1) very dissatisfied; (2) dissatisfied; (3) satisfactory; (4) highly satisfactory; and (5) excellent.

Statistical analysis

The results are expressed as mean ± standard deviation. All statistical analyses were performed using the Statistical Package for the Social Sciences software version 25.0. (SPSS, Inc., Chicago, IL, USA). Definitions: safety index (SI) = postoperative CDVA/preoperative CDVA, efficacy index (EI) = the postoperative UDVA/preoperative CDVA. Kolmogorov–Smirnov test was used for Normality check. We used repeated-ANOVA (Analysis of Variance) to compare the pre- and post-treatment normally distributed data between D- and nD-eyes. One-way ANOVA was used to compare normally distributed data measured only at the last follow-up between the D- and nD-eyes, such as aberration and qCSF test results. Wilcoxon signed-rank test was used for non-normally distributed data. Statistical significance was set at p < 0.05.

Results

Safety

All surgeries were uneventful, and no cataract or retinal detachment was observed in the follow-up. The safety indices of the ICL V4c group at 1 month and 54 months postoperatively were 1.27 ± 0.22 and 1.17 ± 0.30 (p > 0.05), respectively. The corresponding values of the FS-LASIK group were 1.01 ± 0.07 and 0.98 ± 0.20 (p > 0.05), respectively. (p < 0.001 between groups at all time points) Tables 2 and 3 provide the visual and biometric parameters of the D-eyes or nD-eyes between two groups, respectively. Figures 1 and 2 show the CDVA and UDVA (Figs. 1A–C, 2A–C) outcomes of the two groups respectively.

Table 2.

The clinical parameters of the dominant eyes or non-dominant eyes before and after the Implantable Collamer Lens (ICL) V4c implantation or Femtosecond Laser-Assisted Laser in Situ Keratomileusis (FS-LASIK).

Characteristic	D- or nD-eye	Preoperative			1-mon follow-up			54-mon follow-up
		ICL V4c Group	FS-LASIK Group	P	ICL V4c Group	FS-LASIK Group	P	ICL V4c Group	FS-LASIK Group	P
UDVA (Logmar)	D-eye	NA	NA	NA	− 0.05 ± 0.07	− 0.01 ± 0.06*	0.417	0.13 ± 0.12▲	0.15 ± 0.26	0.865
	nD-eye				0.05 ± 0.11	0.26 ± 0.21*	< 0.001	0.25 ± 0.21▲	0.67 ± 0.48▲	< 0.001
Refraction sphere(D)	D-eye	− 10.60 ± 3.18	− 6.94 ± 3.04	0.016	0.17 ± 0.34△	0 ± 0.28△*	0.470	− 0.33 ± 0.39△	− 0.46 ± 0.66△*	0.678
	nD-eye	− 11.50 ± 4.80	− 8.54 ± 4.22	0.049	− 0.17 ± 0.37△	− 1.5 ± 0.96△*	< 0.001	− 0.77 ± 0.67△▲	− 1.98 ± 1.05△▲*	< 0.001
Refraction cylinder(D)	D-eye	− 1.63 ± 1.06	− 0.81 ± 0.51	0.028	− 0.48 ± 0.38△	− 0.13 ± 0.17△	0.009	− 0.48 ± 0.34△▲	− 0.46 ± 0.33△▲	0.895
	nD-eye	− 1.35 ± 1.12	− 0.73 ± 0.66	0.088	− 0.65 ± 0.48△	− 0.23 ± 0.17△	0.003	− 0.50 ± 0.45△▲	− 0.40 ± 0.39△	0.509
SE (D)	D-eye	− 11.42 ± 3.12	− 7.34 ± 3.06	0.008	− 0.07 ± 0.28△	− 0.06 ± 0.27△*	0.963	− 0.57 ± 0.34△	− 0.69 ± 0.67△▲*	0.702
	nD-eye	− 12.18 ± 3.68	− 8.91 ± 4.38	0.031	− 0.49 ± 0.36△	− 1.61 ± 0.96△*	< 0.001	− 1.02 ± 0.70△▲	− 2.18 ± 1.03△▲*	< 0.001
CDVA(Logmar)	D-eye	0.05 ± 0.07	− 0.03 ± 0.06	0.018	− 0.06 ± 0.07△	− 0.02 ± 0.06	0.018	− 0.07 ± 0.10△▲	− 0.02 ± 0.13	0.389
	nD-eye	0.05 ± 0.09	− 0.01 ± 0.10	0.184	− 0.03 ± 0.07△	− 0.01 ± 0.09	0.378	− 0.01 ± 0.15▲	0.04 ± 0.14	0.335
ADD (D)		0.71 ± 0.35	1.33 ± 0.17	0.017	NA	NA	NA	1.38 ± 0.22△	1.81 ± 0.71△	0.174
Safety indices	D-eye	NA	NA	NA	1.30 ± 0.19	0.99 ± 0.05	< 0.001	1.35 ± 0.30	1.00 ± 0.21	0.001
	nD-eye				1.24 ± 0.24	1.04 ± 0.09	0.004	1.21 ± 0.27	0.96 ± 0.20	0.015
Efficacy indices	D-eye	NA	NA	NA	1.29 ± 0.21*	0.96 ± 0.11*	0.003	0.86 ± 0.24	0.73 ± 0.33*	0.286
	nD-eye				1.07 ± 0.34*	0.62 ± 0.30*	< 0.001	0.72 ± 0.37	0.30 ± 0.21*	0.001

D-eye, dominant eye; nD-eye, nondominant eye; UDVA, uncorrected distance visual acuity; ADD, presbyopic add power; SE, spherical equivalent; CDVA, corrected distance visual acuity. △ versus Preoperative, P < 0.05. ▲ versus the 1-month follow-up, P < 0.05. * dominant eye versus nondominant eye, P < 0.05.

Values with statistical significance are shown in bold.

Table 3.

The biometric parameters of the dominant eyes or non-dominant eyes before and after the Implantable Collamer Lens (ICL) V4c implantation or Femtosecond Laser-Assisted Laser in Situ Keratomileusis (FS-LASIK).

Parameters	D- or nD-eye	Preoperative/1-mon follow-up (Vault)			54-mon follow-up
		ICL V4c Group	FS-LASIK Group	P	ICL V4c Group	FS-LASIK Group	P
ACD (mm)	D-eye	3.23 ± 0.32	2.93 ± 0.18	0.013	2.95 ± 0.31△	2.86 ± 0.20	0.419
	nD-eye	3.18 ± 0.33	2.94 ± 0.24	0.041	2.87 ± 0.32△	2.86 ± 0.25	0.980
ACV (μl)	D-eye	180.90 ± 34.45	165.83 ± 26.48	0.344	110.92 ± 19.62△	158.27 ± 30.74	< 0.001
	nD-eye	167.00 ± 31.53	168.83 ± 32.03	0.849	106.33 ± 21.41△	158.73 ± 32.84	< 0.001
ACA (°)	D-eye	39.02 ± 5.82	34.00 ± 5.55	0.046	22.13 ± 3.92△	34.65 ± 5.13	< 0.001
	nD-eye	37.68 ± 5.72	34.48 ± 6.05	0.223	23.50 ± 4.81△	33.15 ± 5.84	< 0.001
CT (μm)	D-eye	530.33 ± 37.26	541.92 ± 22.24	0.375	536.58 ± 38.07	454.08 ± 33.92△	< 0.001
	nD-eye	535.25 ± 39.63	544.67 ± 23.53	0.470	531.92 ± 50.83	460.83 ± 38.74△	< 0.001
IOP (mmhg)	D-eye	15.05 ± 2.64	16.41 ± 3.07	0.007	15.71 ± 2.40△	11.64 ± 2.87△	0.007
	nD-eye	15.17 ± 2.25	16.16 ± 3.43	0.023	16.12 ± 2.00△	11.57 ± 1.89△	0.029
AL (mm)	D-eye	28.34 ± 2.18	26.13 ± 1.19	0.007	28.64 ± 2.33	26.38 ± 1.06	0.007
	nD-eye	28.60 ± 2.09	26.78 ± 1.97	0.023	28.97 ± 2.27	27.16 ± 1.91	0.029
ECD (cell/mm2)	D-eye	3144.42 ± 597.62	NA		2555.42 ± 295.80▲	NA
	nD-eye	3122.67 ± 602.43			2564.42 ± 278.34▲
Vault (μm)	D-eye	559.17 ± 193.08	NA		482.50 ± 220.58▲	NA
	nD-eye	547.50 ± 167.66			489.17 ± 172.28▲

ACD, anterior chamber depth; ACV, anterior chamber volume; ACA, anterior chamber angle; CT, corneal thickness; IOP, intraocular pressure; ECD, endothelium cell density.

△ versus Preoperative, P < 0.05. ▲ versus the 1-month follow-up, P < 0.05. * dominant eye versus nondominant eye, P < 0.05.

Values with statistical significance are shown in bold.

Fig. 1.

Clinical outcomes of 24 eyes (12 dominant eyes and 12 nondominant eyes) with myopia at the last follow-up after implantable collamer lens (ICL V4c) implantation. (A) Postoperative uncorrected distance visual acuity (UDVA) vs. preoperative corrected distance visual acuity (CDVA); (B) Difference between postoperative UDVA and preoperative CDVA; (C) Change in CDVA; (D) Attempted spherical equivalent refraction change versus the achieved spherical equivalent refraction change; (E) Distribution of postoperative spherical equivalent refraction accuracy; (F) Stability of spherical equivalent refraction up to 54 months. D, diopters; Postop, postoperative; Preop, preoperative; mon, month(s).

Fig. 2.

Clinical outcomes of 24 eyes (12 dominant eyes and 12 nondominant eyes) with myopia at the last follow-up after femtosecond laser-assisted in situ keratomileusis (FS-LASIK). (A) Postoperative uncorrected distance visual acuity (UDVA) versus preoperative corrected distance visual acuity (CDVA); (B) Difference between postoperative UDVA and preoperative CDVA; (C) Change in CDVA; (D) Attempted spherical equivalent refraction change versus the achieved spherical equivalent refraction change; (E) Distribution of postoperative spherical equivalent refraction accuracy; (F) Stability of spherical equivalent refraction up to 54 months. D, diopters; Postop, postoperative; Preop, preoperative; mon, month(s).

In the ICL V4c group, the preoperative, 3-months, and 54-months postoperative ECD were 3109.41 ± 126.92 cell/mm², 2767.77 ± 61.1 cell/mm² (vs. preoperative, p = 0.067), and 2571.36 ± 62.02 cell/mm² (vs. preoperative, p = 0.016 and vs. 3-mon postoperative, p = 0.026), respectively.

Efficacy

The efficacy indices of the ICL V4c group and FS-LASIK group were not significant between 1 and 54 months postoperatively (1.12 ± 0.25 and 0.79 ± 0. 07 for ICL V4c group, and 0.79 ± 0.06 and 0.52 ± 0.07 for FS-LASIK group, respectively). The efficacy indices in the ICL V4c group were significantly higher than that of the FS-LASIK group at all time points with all p < 0.01.

Predictability

There was a significant linear correlation in the two groups between the achieved SE and the attempted value (p < 0.001). (Figs. 1D, 2D) At the last follow-up, the SE in 66.67% and 58.33% of the eyes was within ± 0.50 D of the target value and that in 95.83% and 83.33% of the eyes was within ± 1.00 D of the target value in ICL V4c group (Fig. 1E) and FS-LASIK group (Fig. 2E), respectively.

Stability

Spherical equivalent in the ICL V4c group were − 11.80 ± 3.36 D, − 0.28 ± 0.69 D, and − 0.80 ± 0.59 D preoperatively, 1 month, and 54 months postoperatively, respectively. (Fig. 1F) The corresponding figures for the FS-LASIK group were − 8.13 ± 3.78 D, − 0.84 ± 1.05 D, and − 1.43 ± 1.14 D, respectively. (Fig. 2F) The change of SE in two groups were not significantly different between two follow-up time points (− 0.52 ± 0.18 D vs. − 0.59 ± 0.18 D, p = 0.76).

Monovision

The preoperative and 54 months postoperative ADD values of the two groups are shown in Table 2. The progression of presbyopia in ADD was significant in the ICL V4c and FS-LASIK groups (0.69 ± 0.60 D vs. 0.48 ± 0.41 D), and the values were equivalent to 0.14 ± 0.13 D per year and 0.10 ± 0.09 D per year (p = 0.248), respectively. Figures 3A and 4A present the uncorrected visual acuity at near to far distances of two groups at 54 months after ICL V4c implantation, respectively. D-eyes shower advantage in VA at 5.0 m distance (75.00% and 75.00% eyes with 20/32 or better in Snellen lines in two groups, respectively). (Figs. 3B, 4B) nD-eyes shower advantage in VA at 0.4 m distance (100% and 91.67% eyes with 20/32 or better in Snellen lines in two groups, respectively). (Figs. 3C, 4C) Binocular visual acuity in 100%, 91.67%, and 75.00% eyes of ICL V4c group was 20/25 or better in Snellen lines, the corresponding eyes in FS-LASIK group was 83.33%, 83.33%, and 66.67%. (Figs. 3D, 4D).

Fig. 3.

Uncorrected Visual Acuity at near to far distances at 54 months after implantable collamer lens (ICL V4c) implantation. (A) Last follow-up UDVA (logMAR) of Dominant eyes, nonDominant eyes and Binocular. (B) Last follow-up UDVA (Snellen) of the Dominant eyes. (C) Last follow-up UDVA (Snellen) of the Nondominant eyes. (D) Last follow-up Binocular UDVA (Snellen).

Fig. 4.

Uncorrected Visual Acuity at near to far distances at 54 months after femtosecond laser-assisted in situ keratomileusis (FS-LASIK). (A) Last follow-up UDVA (logMAR) of Dominant eyes, nonDominant eyes and Binocular. (B) Last follow-up UDVA (Snellen) of the Dominant eyes. (C) Last follow-up UDVA (Snellen) of the Nondominant eyes. (D) Last follow-up Binocular UDVA (Snellen).

Subjective satisfaction

Supplementary Fig. 1 describes the subjective satisfaction with distance and near VA preoperatively, 3 months postoperatively, and at the last follow-up. In the ICL V4c group, the satisfaction rates (scores 4 or 5) of near VA were 33.3%, 91.67%, and 66.67% respectively, and that of distance VA at three follow-up time points were 0%, 83.33%, and 80.00%, respectively. In the FS-LASIK group, the satisfaction rates of near VA were 33.3%, 83.33%, and 66.67% respectively, and that of distance VA at three follow-up time points were 0%, 83.33%, and 50.00%, respectively.

Aberrations

There was no significant difference in wavefront aberrations between the dominant and non-dominant eyes in the two groups at the last follow-up (Supplementary Fig. 2). There was no significant difference between the two groups in HOAs; however, the FS-LASIK group showed significantly higher coma and spherical aberration, and significantly lower trefoil compared with the ICL V4c group.

qCSF

Table 4 provides the CS at different spatial frequencies at the last follow-up. There was a significant difference between the dominant and non-dominant eyes in CS at 1.0–3.0 cpd AULCSF and CSF Acuity in the FS-LASIK group. (Fig. 5A,B). There was no significant difference between the dominant and non-dominant eyes in ICL V4c group or binocular comparison of the two groups (Fig. 5C).

Table 4.

Quick contrast sensitivity function (qCSF) results of the dominant eyes or non-dominant eyes at different spatial frequencies 54-mon after the Implantable Collamer Lens (ICL) V4c or Femtosecond Laser-Assisted Laser in Situ Keratomileusis (FS-LASIK).

Parameters	D- or nD-eye	ICL V4c Group	FS-LASIK Group	P
CSF Acuity	D-eye	10.16 ± 4.32	10.64 ± 5.98	0.602
	nD-eye	7.13 ± 5.41	6.38 ± 7.08	0.919
AULCSF	D-eye	0.58 ± 0.19	0.57 ± 0.23*	0.750
	nD-eye	0.37 ± 0.28	0.31 ± 0.32*	0.839
CS (1.0 cpd)	D-eye	1.18 ± 0.09	1.12 ± 0.19*	0.673
	nD-eye	1.07 ± 0.31	0.80 ± 0.51*	0.043
CS (1.5 cpd)	D-eye	1.14 ± 0.11	1.08 ± 0.23*	0.642
	nD-eye	0.95 ± 0.31	0.74 ± 0.48*	0.114
CS (3.0 cpd)	D-eye	0.85 ± 0.31	0.82 ± 0.37*	0.851
	nD-eye	0.55 ± 0.38	0.45 ± 0.39*	0.478
CS (6.0 cpd)	D-eye	0.40 ± 0.34	0.42 ± 0.41	0.904
	nD-eye	0.16 ± 0.32	0.16 ± 0.34	0.995
CS (12.0 cpd)	D-eye	0.07 ± 0.11	0.12 ± 0.20	0.427
	nD-eye	0.05 ± 0.17	0.08 ± 0.20	0.734
CS (18.0 cpd)	D-eye	0 ± 0.01	0.02 ± 0.05	0.543
	nD-eye	0.02 ± 0.06	0.02 ± 0.08	0.830

AULCSF, Area Under Log CSF; D-eye, dominant eye; nD-eye, nondominant eye; CS, contrast sensitivity.

*Dominant eye versus nondominant eye, P < 0.05.

Values with statistical significance are shown in bold.

Fig. 5.

Quantitative Contrast Sensitivity (qCSF) test results of Dominant eyes, nonDominant eyes in ICL V4c group (A) and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) group (B) and Binocular results (C). *: Dominant eyes vs. nonDominant eyes, p < 0.05, # ICL V4c vs. FS-LASIK, P < 0.05.

Discussion

This study provides further support for 4.5 years long-term safety of ICL V4c implantation and FS-LASIK for myopia correction in the presbyopia age patients. Monovision surgery using ICL V4c or FS-LASIK provides long-term safety and good binocular vision in myopic presbyopes.

Previous studies comparing FS-LASIK and SMILE have provided evidence regarding the safety and efficacy of both procedures in both short-term and long-term follow-up assessments^17,19–21. The safety index was found to be 1.17 for ICL V4c implantation and 0.98 for FS-LASIK, which is comparable to the safety index of 1.22 observed in a previous study involving patients over 40 years who underwent ICL V4c implantation during a 43-month follow-up period²². In cases where myopia exceeds -11.00D, FS-LASIK demonstrates feasibility as well as comparable safety and efficacy with ICL V4c, while SMILE may have limitations^23–25. Therefore, this study opted for FS-LASIK instead of SMILE when comparing it with ICL V4c implantation due to the anticipation of including more subjects with high or ultra-high myopia in the ICL V4c groups. In the clinical research center of this study, ICL V4c implantation are more expensive than FS-LASIK, in that case, patients might choose FS-LASIK prior to ICL V4c implantation when they meet the indication of the two procedures. Meanwhile, that was the reason of the inadequate match between two groups, a part of patients who choose ICL V4c implantation were out of the indication of FS-LASIK. The ICL V4c demonstrated a higher SI at the last follow-up, which was consistent with the enhanced object image effect achieved by ICL compared to LASIK²⁶. There was no significant difference in ECD between the preoperative and 3-month postoperative levels, indicating an annual decrease rate of 1.75% in the ICL V4c group. Previous studies have reported a decrease rate of 0.6% per year in healthy adults²⁷ and 0.93–4% per year in long-term follow-up after ICL implantation^28,29. The relatively higher ECD decrease rates observed might be associated with older age. At the last follow-up, all subjects had an ECD greater than 2000 cells/mm², confirming the safety of both ICL V4c implantation and FS-LASIK for myopia correction in this age group.Efficacy indices data are biased due to monovision design in this study, because the intentionally undercorrected non-dominant eyes have lower efficacy indices. Our previous findings suggested that binocular visual acuity at near-to-far distances might be better than simple efficacy indices in the assessment of monovision design.

In predictability, Our results were similar to a previous study with 96.67% of eyes within ± 1.00D of the target value in patients over 40 years old underwent ICL V4c implantation²⁸. Progressed myopia with − 0.52 D and − 0.59 D in two groups was acceptable in 54-months follow-up^8,30. Patients were counselled about the possibility of myopia progression especially in patient over − 10.00 D before surgery in this study. The results be a reference to clinical practice and preoperative counsel.

The ADD progression rates were similar between ICL V4c group (0.10 D per year), FS-LASIK group (0.14 D per year), and a previous study (0.17 D per year)²². Monovision surgery using ICL V4c or FS-LASIK provides similarly good binocular VA at near-to-far distance. These results and the subjective satisfaction results agree with previous findings (81.25% for near VA and 87.50% for distance VA)²². The decreased satisfaction rate of near VA might be explained with the relatively higher ADD progression in the ICL V4c group (0.69 D vs. 0.48D), while that of distance VA might be correlated to higher preoperative ADD in the FS-LASIK group (1.33 D vs. 0.71 D), as more refraction sphere was reserved in nD-eyes in this group. Besides, the short-term satisfaction included partial psychological factors like immediately improved visual experience, and this part of the subjective satisfaction may decrease in the long-term follow-up.

The trefoil aberration was significant higher in ICL V4c group than FS-LASIK group. There are several possible explanations: firstly, the centre of ICL might deviate from the visual axis³¹; seconds, higher trefoil aberration might be attributed to the corneal incision³¹; third, the pupil dilation under scotopic environment in aberration measurement, as the optical zone might be relatively smaller in ICL V4c groups^32,33. Meanwhile, FS-LASIK might introduce coma and spherical aberration due to eccentric ablation³⁴.

The novel qCSF test was firstly applied for CSF evaluation between D-eye and nD-eye in monovision surgery utilizing ICL V4c implantation and FS-LASIK. A previous study reported that age instead of refraction error was significant correlated with qCSF readings^35,36. Previous study reported similar contrast sensitivity outcomes of the 3 methods—PRK, FS-LASIK, and SMILE—in patients with mild and moderate myopia³⁷. While in the high myopia patients in this study, compared with the FS-LASIK group, the ICL V4c group showed high readings of CS in nD-eyes in low spatial frequency, which might be attributed by the retinal magnification after ICL implantation²⁶.

This study had several limitations: first, it was a single-centre study with relatively small size of participants. Multicentre studies with larger sample size are needed to provide high-quality clinical evidence; second, the study did not include the preoperative results of aberration and qCSF test due to the upgrading of equipment. More reliable measurements are suggested on the long-term follow-up preoperative and postoperative test for aberrations and contrast sensitivity function data; third, inadequate match between the ICL V4c group and the FS-LASIK group, which was limited by the differences of characteristics and indications of the two surgeries. FS-LAISK is potentially used to correct high myopia, though ICL V4c shows better performance in superhigh myopia correction. A better-matched pair study would provide more solid evidence; fourth, there is no clear breakdown of the changes and trends observed at intermediate time points. The enrolled patients got followed-up at different time points, making it difficult to analysis and get a solid conclusion, a more rigorous plan in the follow- up will help in the trends observation.

In conclusion, Monovision surgery using ICL V4c or FS-LASIK are practicable for correction of myopia in patients in the presbyopia age group, with long-term efficacy and good subjective satisfaction at near and far distances.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Author contributions

Study concept and design (YY, YX, ZZ, JZ, XZ); data collection (YY, YX, ZZ, FL, LN, WS, XW, JZ); data analysis and interpretation (YY, FL); drafting of the manuscript (YY, FL, JZ, XZ); critical revision of the manuscript (JZ, XZ); supervision (XZ). All authors read and approved the final manuscript.

Funding

National Key Research and Development Program of China (2024YFC2510805); Key Project of the Regional Innovation and Development Joint Fund of the National Natural Science Foundation of China(U24A20708); Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000); National Natural Science Foundation of China (Grant No. 82271119, 82471116); Shanghai Rising-Star Program (23QA1401000); Healthy Young Talents Project of Shanghai Municipal Health Commission (2022YQ015); Shanghai Oriental Talents-Technology Platform Program (QNKJ2024055).

Data availability

The datasets generated and/or analysed during the current study are not publicly available due funding requirement but are available from the corresponding author on reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Statement of Ethics

This study followed the tenets of the Declaration of Helsinki and was approved by the ethics committee of the Eye and ENT Hospital of Fudan University (approval number: 2013015). Informed consent was obtained from all participants.

Consent for publication

Written informed consent was obtained from the patients for the publication of this paper. Patient names and the eyes/facial region of study participants is not applicable.